Tonix Stock Climbs After New TONMYA Coverage Deal

Key Agreement Boosts Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp, ticker TNXP, saw its shares increase by 5.1 percent following the announcement of a significant coverage agreement with a group purchasing organization, GPO. The agreement, effective May 1, expands access for the company's key fibromyalgia treatment.

Expanded Market Access Overview

The new GPO agreement grants insurance coverage for TONMYA to approximately 35 million commercial lives in the United States. This represents about 20 percent of the total commercial market. TONMYA is a cyclobenzaprine HCl sublingual tablet and is the first FDA-approved treatment for fibromyalgia in adults in over a decade. The company also confirmed that TONMYA is already covered under Medicaid in 38 states, reaching approximately 55 million individuals.

Impact on Market Position

This development positively impacts Tonix's market penetration strategy. The expanded commercial coverage, combined with existing government program access, strengthens the revenue potential for TONMYA. The stock's immediate rise reflects investor confidence in the company's ability to commercialize its flagship product effectively. Discussions with Medicare and Medicaid are ongoing to further broaden access.

Summary and Outlook

The GPO agreement is a critical step for Tonix Pharmaceuticals, significantly widening the commercial reach of TONMYA. Market observers will now watch for progress in ongoing discussions with Medicare and other payors, which could further drive the drug's adoption and impact the company's financial performance.

FAQ

Q: Why did Tonix Pharmaceuticals stock increase?
A: The stock rose 5.1% after the company announced a new GPO coverage agreement for its fibromyalgia drug, TONMYA, expanding access to 35 million commercial lives.

Q: What is TONMYA?
A: TONMYA is the first FDA-approved treatment for fibromyalgia in adults in more than 15 years. It is a non-opioid analgesic for daily bedtime use.

Q: What is the current coverage for TONMYA?
A: It is now covered for 35 million commercial lives through a GPO deal and 55 million Medicaid lives across 38 states.

Source: Investing.com